Tyh1 personal page - To The Moon

Tyh1

Tyh1

No personal profile

11Follow

2Followers

0Topic

0Badge

2021-08-03

$XPeng Inc.(XPEV)$$$$

2021-07-27

Ok

Dow, S&P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting

2021-07-22

Gyghhhhh

2 High-Risk, High-Reward Stocks That Could Go to the Moon

2021-06-29

$NIO Inc.(NIO)$[Miser] [Miser] [Miser]

2021-06-29

Waiting for below $20

2021-06-28

$NIO Inc.(NIO)$[Miser] $50 tonight

2021-06-28

giggle

Sorry, the original content has been removed

2021-06-28

[Smile]

The Fed’s inflation view could drag the economy into recession, El-Erian warns

2021-06-24

[Glance]

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586648044185069","uuid":"3586648044185069","gmtCreate":1623554020745,"gmtModify":1624547800483,"name":"Tyh1","pinyin":"tyh1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":11,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":804335985,"gmtCreate":1627920967347,"gmtModify":1703498003834,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","text":"$XPeng Inc.(XPEV)$$$$","images":[{"img":"https://static.tigerbbs.com/72e0fa37cc7f2667fb941564466feb83","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804335985","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":803999340,"gmtCreate":1627399466680,"gmtModify":1703489273864,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803999340","repostId":"2154961091","repostType":2,"repost":{"id":"2154961091","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627331280,"share":"https://ttm.financial/m/news/2154961091?lang=&edition=fundamental","pubTime":"2021-07-27 04:28","market":"hk","language":"en","title":"Dow, S&P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2154961091","media":"Dow Jones","summary":"MW Dow, S&P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting\n\n\n  By William Wat","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Dow, S&amp;P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting\n</p>\n<p>\n  By William Watts and Joy Wiltermuth \n</p>\n<p>\n  U.S. stock benchmarks closed at back-to-back records Monday, as investors await earnings this week from corporate heavyweights, including from Big Tech, and a Federal Reserve policy meeting. \n</p>\n<p>\n  The pipeline of earnings could set the tone, analysts said, but investors also will be focused on China and the U.S. as tensions rise between the world's top two economies. \n</p>\n<p>\n  How did major indexes perform? \n</p>\n<p>\n  U.S. benchmarks bounced back sharply last week from a July 19 tumble to end Friday at records. The S&amp;P 500 on Friday rose 2% to finish at its 40th record close of 2021, and the tech-heavy Nasdaq Composite rose 2.8%. The Dow also pushed to a record close Friday, finishing above the 35,000 milestone  for the first time. \n</p>\n<p>\n  What driving the market? \n</p>\n<p>\n  U.S. stocks rallied to fresh intraday and closing records Monday, shaking off a softer tone across global equity markets as investors waited to hear from the C-suites of Big Tech companies about their expectations for the rest of 2021. \n</p>\n<p>\n  \"It's all about earnings this week,\" said John Carey, director for equity income at Amundi U.S., adding that investors will be glued to what company executives have to say about their expectations for the second half of this year. \n</p>\n<p>\n  \"I think investors will also be especially attuned to anything management has to say about inflation, cost pressures and the margin outlook, as a result of potentially rising labor costs and other inputs,\" he told MarketWatch. \n</p>\n<p>\n  Results are due this week from major tech companies including Alphabet Inc.<a href=\"https://laohu8.com/S/GOOGL\">$(GOOGL)$</a>(GOOGL), Amazon.com Inc. <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, Apple Inc.<a href=\"https://laohu8.com/S/AAPL\">$(AAPL)$</a>, <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc.(FB) and Microsoft Corp.<a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a>. \n</p>\n<p>\n  Earnings Preview: Apple, Microsoft, Google, Facebook, Amazon and Tesla headline the biggest week of earnings  \n</p>\n<p>\n  \"The earnings season is now in full throttle and thus far continues to surprise to the upside, as most companies are reporting better than expected top and bottom-line results,\" said Peter Cardillo, chief market economist at Spartan Capital Securities, in a note. \n</p>\n<p>\n  The U.S. earnings calendar also includes electric-vehicle maker Tesla Inc.<a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, which reported after the close on Monday . \n</p>\n<p>\n  \"Folks are non-committed to jumping in front of the big earnings we have on for this week,\" said Robert Pavlik, a senior portfolio manager at Dakota Wealth Management. \"Earnings are not the concern. It's the market's reaction to earnings.\" \n</p>\n<p>\n  But Pavlik also expects investors to focus on the outcome of the Federal Reserve's two-day policy meeting, particularly if the delta variant of the coronavirus that causes COVID-19 begins to weigh down the central bank's plans to eventually tighten its extremely accommodative monetary policies. \n</p>\n<p>\n  \"If this trend continues with the COVID variant this fall and winter, the Fed may not be able to raise interest rates [in 2023] as much as they want to, unless the economy really picks up steam,\" he told MarketWatch. \n</p>\n<p>\n  Don't miss:Stagflation is 'a legitimate risk' that would be painful for U.S. markets  \n</p>\n<p>\n  The Fed meets Tuesday and Wednesday. Policy makers are expected to discuss plans around eventually slowing the pace of the Fed's monthly bond purchases. But investors expecting clear answers about the crucial questions of when the tapering will start and the pace of any pullback will likely be disappointed, economists said. \n</p>\n<p>\n  See:Fed to tiptoe toward tapering this week  \n</p>\n<p>\n  In Washington, the Biden administration on Monday  said it was confident that a bipartisan infrastructure deal still can be worked out, despite setbacks over the weekend. \n</p>\n<p>\n  Global stocks in Europe and the U.K. closed modestly lower, while Hong Kong's Hang Seng  skidded over 4%, following a crackdown by China  shares fell 3% after dropping as much as 14% in premarket action. \n</p>\n<p>\n  U.S. government data on Monday showed U.S. new home sales fell 6.6% in June  to an annual rate of 676,000, the lowest since the first month of the COVID-19 pandemic in early 2020, as high prices and a limited selection appeared to frustrate would-be buyers. \n</p>\n<p>\n  Also read:Goldman Sachs trims U.S. growth outlook due to weaker service sector  \n</p>\n<p>\n  Which companies were in focus? \n</p>\n<p>\n  What did other markets do? \n</p>\n<p>\n  Steven Goldstein contributed reporting \n</p>\n<p>\n  -William Watts; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  July 26, 2021 16:28 ET (20:28 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow, S&P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow, S&P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-27 04:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Dow, S&amp;P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting\n</p>\n<p>\n  By William Watts and Joy Wiltermuth \n</p>\n<p>\n  U.S. stock benchmarks closed at back-to-back records Monday, as investors await earnings this week from corporate heavyweights, including from Big Tech, and a Federal Reserve policy meeting. \n</p>\n<p>\n  The pipeline of earnings could set the tone, analysts said, but investors also will be focused on China and the U.S. as tensions rise between the world's top two economies. \n</p>\n<p>\n  How did major indexes perform? \n</p>\n<p>\n  U.S. benchmarks bounced back sharply last week from a July 19 tumble to end Friday at records. The S&amp;P 500 on Friday rose 2% to finish at its 40th record close of 2021, and the tech-heavy Nasdaq Composite rose 2.8%. The Dow also pushed to a record close Friday, finishing above the 35,000 milestone  for the first time. \n</p>\n<p>\n  What driving the market? \n</p>\n<p>\n  U.S. stocks rallied to fresh intraday and closing records Monday, shaking off a softer tone across global equity markets as investors waited to hear from the C-suites of Big Tech companies about their expectations for the rest of 2021. \n</p>\n<p>\n  \"It's all about earnings this week,\" said John Carey, director for equity income at Amundi U.S., adding that investors will be glued to what company executives have to say about their expectations for the second half of this year. \n</p>\n<p>\n  \"I think investors will also be especially attuned to anything management has to say about inflation, cost pressures and the margin outlook, as a result of potentially rising labor costs and other inputs,\" he told MarketWatch. \n</p>\n<p>\n  Results are due this week from major tech companies including Alphabet Inc.<a href=\"https://laohu8.com/S/GOOGL\">$(GOOGL)$</a>(GOOGL), Amazon.com Inc. <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, Apple Inc.<a href=\"https://laohu8.com/S/AAPL\">$(AAPL)$</a>, <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc.(FB) and Microsoft Corp.<a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a>. \n</p>\n<p>\n  Earnings Preview: Apple, Microsoft, Google, Facebook, Amazon and Tesla headline the biggest week of earnings  \n</p>\n<p>\n  \"The earnings season is now in full throttle and thus far continues to surprise to the upside, as most companies are reporting better than expected top and bottom-line results,\" said Peter Cardillo, chief market economist at Spartan Capital Securities, in a note. \n</p>\n<p>\n  The U.S. earnings calendar also includes electric-vehicle maker Tesla Inc.<a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, which reported after the close on Monday . \n</p>\n<p>\n  \"Folks are non-committed to jumping in front of the big earnings we have on for this week,\" said Robert Pavlik, a senior portfolio manager at Dakota Wealth Management. \"Earnings are not the concern. It's the market's reaction to earnings.\" \n</p>\n<p>\n  But Pavlik also expects investors to focus on the outcome of the Federal Reserve's two-day policy meeting, particularly if the delta variant of the coronavirus that causes COVID-19 begins to weigh down the central bank's plans to eventually tighten its extremely accommodative monetary policies. \n</p>\n<p>\n  \"If this trend continues with the COVID variant this fall and winter, the Fed may not be able to raise interest rates [in 2023] as much as they want to, unless the economy really picks up steam,\" he told MarketWatch. \n</p>\n<p>\n  Don't miss:Stagflation is 'a legitimate risk' that would be painful for U.S. markets  \n</p>\n<p>\n  The Fed meets Tuesday and Wednesday. Policy makers are expected to discuss plans around eventually slowing the pace of the Fed's monthly bond purchases. But investors expecting clear answers about the crucial questions of when the tapering will start and the pace of any pullback will likely be disappointed, economists said. \n</p>\n<p>\n  See:Fed to tiptoe toward tapering this week  \n</p>\n<p>\n  In Washington, the Biden administration on Monday  said it was confident that a bipartisan infrastructure deal still can be worked out, despite setbacks over the weekend. \n</p>\n<p>\n  Global stocks in Europe and the U.K. closed modestly lower, while Hong Kong's Hang Seng  skidded over 4%, following a crackdown by China  shares fell 3% after dropping as much as 14% in premarket action. \n</p>\n<p>\n  U.S. government data on Monday showed U.S. new home sales fell 6.6% in June  to an annual rate of 676,000, the lowest since the first month of the COVID-19 pandemic in early 2020, as high prices and a limited selection appeared to frustrate would-be buyers. \n</p>\n<p>\n  Also read:Goldman Sachs trims U.S. growth outlook due to weaker service sector  \n</p>\n<p>\n  Which companies were in focus? \n</p>\n<p>\n  What did other markets do? \n</p>\n<p>\n  Steven Goldstein contributed reporting \n</p>\n<p>\n  -William Watts; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  July 26, 2021 16:28 ET (20:28 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF","GOOG":"谷歌","GOOGL":"谷歌A","NDAQ":"纳斯达克OMX交易所",".IXIC":"NASDAQ Composite"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154961091","content_text":"MW Dow, S&P 500 and Nasdaq end at records ahead of Big Tech earnings, Fed meeting\n\n\n  By William Watts and Joy Wiltermuth \n\n\n  U.S. stock benchmarks closed at back-to-back records Monday, as investors await earnings this week from corporate heavyweights, including from Big Tech, and a Federal Reserve policy meeting. \n\n\n  The pipeline of earnings could set the tone, analysts said, but investors also will be focused on China and the U.S. as tensions rise between the world's top two economies. \n\n\n  How did major indexes perform? \n\n\n  U.S. benchmarks bounced back sharply last week from a July 19 tumble to end Friday at records. The S&P 500 on Friday rose 2% to finish at its 40th record close of 2021, and the tech-heavy Nasdaq Composite rose 2.8%. The Dow also pushed to a record close Friday, finishing above the 35,000 milestone  for the first time. \n\n\n  What driving the market? \n\n\n  U.S. stocks rallied to fresh intraday and closing records Monday, shaking off a softer tone across global equity markets as investors waited to hear from the C-suites of Big Tech companies about their expectations for the rest of 2021. \n\n\n  \"It's all about earnings this week,\" said John Carey, director for equity income at Amundi U.S., adding that investors will be glued to what company executives have to say about their expectations for the second half of this year. \n\n\n  \"I think investors will also be especially attuned to anything management has to say about inflation, cost pressures and the margin outlook, as a result of potentially rising labor costs and other inputs,\" he told MarketWatch. \n\n\n  Results are due this week from major tech companies including Alphabet Inc.$(GOOGL)$(GOOGL), Amazon.com Inc. $(AMZN)$, Apple Inc.$(AAPL)$, Facebook Inc.(FB) and Microsoft Corp.$(MSFT)$. \n\n\n  Earnings Preview: Apple, Microsoft, Google, Facebook, Amazon and Tesla headline the biggest week of earnings  \n\n\n  \"The earnings season is now in full throttle and thus far continues to surprise to the upside, as most companies are reporting better than expected top and bottom-line results,\" said Peter Cardillo, chief market economist at Spartan Capital Securities, in a note. \n\n\n  The U.S. earnings calendar also includes electric-vehicle maker Tesla Inc.$(TSLA)$, which reported after the close on Monday . \n\n\n  \"Folks are non-committed to jumping in front of the big earnings we have on for this week,\" said Robert Pavlik, a senior portfolio manager at Dakota Wealth Management. \"Earnings are not the concern. It's the market's reaction to earnings.\" \n\n\n  But Pavlik also expects investors to focus on the outcome of the Federal Reserve's two-day policy meeting, particularly if the delta variant of the coronavirus that causes COVID-19 begins to weigh down the central bank's plans to eventually tighten its extremely accommodative monetary policies. \n\n\n  \"If this trend continues with the COVID variant this fall and winter, the Fed may not be able to raise interest rates [in 2023] as much as they want to, unless the economy really picks up steam,\" he told MarketWatch. \n\n\n  Don't miss:Stagflation is 'a legitimate risk' that would be painful for U.S. markets  \n\n\n  The Fed meets Tuesday and Wednesday. Policy makers are expected to discuss plans around eventually slowing the pace of the Fed's monthly bond purchases. But investors expecting clear answers about the crucial questions of when the tapering will start and the pace of any pullback will likely be disappointed, economists said. \n\n\n  See:Fed to tiptoe toward tapering this week  \n\n\n  In Washington, the Biden administration on Monday  said it was confident that a bipartisan infrastructure deal still can be worked out, despite setbacks over the weekend. \n\n\n  Global stocks in Europe and the U.K. closed modestly lower, while Hong Kong's Hang Seng  skidded over 4%, following a crackdown by China  shares fell 3% after dropping as much as 14% in premarket action. \n\n\n  U.S. government data on Monday showed U.S. new home sales fell 6.6% in June  to an annual rate of 676,000, the lowest since the first month of the COVID-19 pandemic in early 2020, as high prices and a limited selection appeared to frustrate would-be buyers. \n\n\n  Also read:Goldman Sachs trims U.S. growth outlook due to weaker service sector  \n\n\n  Which companies were in focus? \n\n\n  What did other markets do? \n\n\n  Steven Goldstein contributed reporting \n\n\n  -William Watts; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  July 26, 2021 16:28 ET (20:28 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172537894,"gmtCreate":1626965686918,"gmtModify":1703481587635,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"Gyghhhhh","listText":"Gyghhhhh","text":"Gyghhhhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172537894","repostId":"2153755876","repostType":4,"repost":{"id":"2153755876","pubTimestamp":1626959340,"share":"https://ttm.financial/m/news/2153755876?lang=&edition=fundamental","pubTime":"2021-07-22 21:09","market":"us","language":"en","title":"2 High-Risk, High-Reward Stocks That Could Go to the Moon","url":"https://stock-news.laohu8.com/highlight/detail?id=2153755876","media":"Motley Fool","summary":"Risk-averse investors may want to look elsewhere.","content":"<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.</p>\n<p>But others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: <b>Planet 13 Holdings</b> (OTC:PLNH.F) and <b>Cassava Sciences</b> (NASDAQ:SAVA).</p>\n<p><img src=\"https://static.tigerbbs.com/74a895bc6e17c8f58a2b42d63ee986c8\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>PLNHF data by YCharts</p>\n<h3>1. Planet 13 Holdings</h3>\n<p>Wall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most innovative business models.</p>\n<p>The company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.</p>\n<p>With a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.</p>\n<p>Planet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including <a href=\"https://laohu8.com/S/NWY\">New York</a> <a href=\"https://laohu8.com/S/CHCO\">City</a>, <a href=\"https://laohu8.com/S/WASH\">Washington</a> D.C., and Miami.</p>\n<p>This master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.</p>\n<p>Management's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the <a href=\"https://laohu8.com/S/AONE.U\">one</a> in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.</p>\n<p>If Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634051%2Fmature-person-sits-in-a-red-chair-in-front-of-a-large-window-contemplating-something-while-looking-at-a-tablet.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images</p>\n<h3>2. Cassava Sciences</h3>\n<p>Shares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.</p>\n<p>According to the company, \"the ability to improve&nbsp;multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.</p>\n<p>Even though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>'s AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.</p>\n<p>So what makes Cassava Sciences a risky stock to buy?</p>\n<p>Before the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.</p>\n<p>At least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though&nbsp;that also means the potential rewards could be huge.</p>\n<p>Cassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> comfortable with the risk should consider initiating a (small) position in this healthcare stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Risk, High-Reward Stocks That Could Go to the Moon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Risk, High-Reward Stocks That Could Go to the Moon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153755876","content_text":"There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.\nBut others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: Planet 13 Holdings (OTC:PLNH.F) and Cassava Sciences (NASDAQ:SAVA).\n\nPLNHF data by YCharts\n1. Planet 13 Holdings\nWall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has one of the most innovative business models.\nThe company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.\nWith a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.\nPlanet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including New York City, Washington D.C., and Miami.\nThis master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.\nManagement's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the one in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.\nIf Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.\n\nImage source: Getty Images\n2. Cassava Sciences\nShares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.\nAccording to the company, \"the ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.\nEven though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of Biogen's AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.\nSo what makes Cassava Sciences a risky stock to buy?\nBefore the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.\nAt least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though that also means the potential rewards could be huge.\nCassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. Investors comfortable with the risk should consider initiating a (small) position in this healthcare stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159472506,"gmtCreate":1624978577105,"gmtModify":1703849403345,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"$NIO Inc.(NIO)$[Miser] [Miser] [Miser]","images":[{"img":"https://static.tigerbbs.com/c71510cff390968cf52d2f909c1b49f9","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159472506","isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159478492,"gmtCreate":1624978507716,"gmtModify":1703849400597,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"Waiting for below&nbsp;$20","listText":"Waiting for below&nbsp;$20","text":"Waiting for below $20","images":[{"img":"https://static.tigerbbs.com/d13900ebf95ba98e9c5cf77a09cbea9b","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159478492","isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150811111,"gmtCreate":1624892432233,"gmtModify":1703847330356,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","text":"$NIO Inc.(NIO)$[Miser] $50 tonight","images":[{"img":"https://static.tigerbbs.com/c362e6005baec74dd0f915cdeb7a57fd","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150811111","isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150810288,"gmtCreate":1624892341544,"gmtModify":1703847326146,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"giggle&nbsp;","listText":"giggle&nbsp;","text":"giggle","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150810288","repostId":"2146027870","repostType":4,"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150837286,"gmtCreate":1624892309345,"gmtModify":1703847324691,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/150837286","repostId":"1129950691","repostType":4,"repost":{"id":"1129950691","pubTimestamp":1624891529,"share":"https://ttm.financial/m/news/1129950691?lang=&edition=fundamental","pubTime":"2021-06-28 22:45","market":"us","language":"en","title":"The Fed’s inflation view could drag the economy into recession, El-Erian warns","url":"https://stock-news.laohu8.com/highlight/detail?id=1129950691","media":"CNBC","summary":"KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Er","content":"<div>\n<p>KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Erian told CNBC on Monday.\n“Every day I see evidence of inflation not being transitory, and I have ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed’s inflation view could drag the economy into recession, El-Erian warns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed’s inflation view could drag the economy into recession, El-Erian warns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 22:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Erian told CNBC on Monday.\n“Every day I see evidence of inflation not being transitory, and I have ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1129950691","content_text":"KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Erian told CNBC on Monday.\n“Every day I see evidence of inflation not being transitory, and I have concern that the Fed is falling behind,” he said.\nCentral bank leaders insist that the recent round of inflation will subside once short-term supply chain bottlenecks clear and 2020 data fades from comparisons.\n\nFederal Reserve officials are underestimating inflation and risking that the U.S. could fall into another recession, Mohamed El-Erian, the Allianz chief economic advisor, told CNBC on Monday.\nCentral bank leaders insist that the recent round of price pressures will subside once short-term supply chain bottlenecks clear and the 2020 economic shutdown period is no longer part of the year-over-year comparisons.\nBut El-Erian said he sees growing evidence that the Fed is wrong.\n“I have concerns about the inflation story,” he told CNBC’s Becky Quick during a “Squawk Box” interview. “Every day I see evidence of inflation not being transitory, and I have concern that the Fed is falling behind and that it may have to play catch-up, and history makes you very uncomfortable if you end up in a world in which the Fed has to play catch-up.”\nIf the Fed does fall into that position, it may have to raise interest rates and otherwise tighten monetary policy sooner than it would like.\n“Normally, we end up with a recession because you have to slam on the brakes as opposed to slowly taking your foot off the accelerator, which is what believe is going to happen,” El-Erian said.\nThe economy is still technically in a recession that began in February 2020, according to the National Bureau of Economic Research, considered the official arbiter in such matters. However, real GDP is just a shade below where it was when the downturn started and is likely to pass that level when the second quarter data comes in.\nInflation, though, has thwarted recoveries in the past, and recent data tell conflicting stories about the current pace.\nThe Fed’s favorite gauge, the personal consumption expenditures price index excluding the volatile food and energy sectors, in May rose 3.4% from a year ago, the highest level since 1992 an well above the central bank’s 2% target.\nThat came after a 5% increase in the consumer price indexand a6.6% burst in the producer price index, both well higher than anything the U.S. has seen since at least before the financial crisis.\nBut much of the price pressures have come in areas particularly germane to the economic recovery – used car prices, air fares, hotel prices and the like.\nWhile Fed officials see those factors abating in the coming months, El-Erian said he’s not so sure, even if the financial markets don’t seem to care.\n“If you were actually to look at the numbers on inflation, you would start having serious doubts in your mind as to how transitory inflation is,” El-Erian said. “But as long as the Fed believes it’s transitory, that is what matters for markets.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126181559,"gmtCreate":1624547575071,"gmtModify":1703840110096,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586648044185069","idStr":"3586648044185069"},"themes":[],"htmlText":"[Glance]&nbsp;","listText":"[Glance]&nbsp;","text":"[Glance]","images":[{"img":"https://static.tigerbbs.com/f96a3fd5594599594dd744ab43b84bcc","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126181559","isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":150811111,"gmtCreate":1624892432233,"gmtModify":1703847330356,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","text":"$NIO Inc.(NIO)$[Miser] $50 tonight","images":[{"img":"https://static.tigerbbs.com/c362e6005baec74dd0f915cdeb7a57fd","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150811111","isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150837286,"gmtCreate":1624892309345,"gmtModify":1703847324691,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/150837286","repostId":"1129950691","repostType":4,"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804335985,"gmtCreate":1627920967347,"gmtModify":1703498003834,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","text":"$XPeng Inc.(XPEV)$$$$","images":[{"img":"https://static.tigerbbs.com/72e0fa37cc7f2667fb941564466feb83","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804335985","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159472506,"gmtCreate":1624978577105,"gmtModify":1703849403345,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"$NIO Inc.(NIO)$[Miser] [Miser] [Miser]","images":[{"img":"https://static.tigerbbs.com/c71510cff390968cf52d2f909c1b49f9","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159472506","isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150810288,"gmtCreate":1624892341544,"gmtModify":1703847326146,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"giggle&nbsp;","listText":"giggle&nbsp;","text":"giggle","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150810288","repostId":"2146027870","repostType":4,"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803999340,"gmtCreate":1627399466680,"gmtModify":1703489273864,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803999340","repostId":"2154961091","repostType":2,"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172537894,"gmtCreate":1626965686918,"gmtModify":1703481587635,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Gyghhhhh","listText":"Gyghhhhh","text":"Gyghhhhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172537894","repostId":"2153755876","repostType":4,"repost":{"id":"2153755876","pubTimestamp":1626959340,"share":"https://ttm.financial/m/news/2153755876?lang=&edition=fundamental","pubTime":"2021-07-22 21:09","market":"us","language":"en","title":"2 High-Risk, High-Reward Stocks That Could Go to the Moon","url":"https://stock-news.laohu8.com/highlight/detail?id=2153755876","media":"Motley Fool","summary":"Risk-averse investors may want to look elsewhere.","content":"<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.</p>\n<p>But others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: <b>Planet 13 Holdings</b> (OTC:PLNH.F) and <b>Cassava Sciences</b> (NASDAQ:SAVA).</p>\n<p><img src=\"https://static.tigerbbs.com/74a895bc6e17c8f58a2b42d63ee986c8\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>PLNHF data by YCharts</p>\n<h3>1. Planet 13 Holdings</h3>\n<p>Wall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most innovative business models.</p>\n<p>The company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.</p>\n<p>With a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.</p>\n<p>Planet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including <a href=\"https://laohu8.com/S/NWY\">New York</a> <a href=\"https://laohu8.com/S/CHCO\">City</a>, <a href=\"https://laohu8.com/S/WASH\">Washington</a> D.C., and Miami.</p>\n<p>This master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.</p>\n<p>Management's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the <a href=\"https://laohu8.com/S/AONE.U\">one</a> in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.</p>\n<p>If Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634051%2Fmature-person-sits-in-a-red-chair-in-front-of-a-large-window-contemplating-something-while-looking-at-a-tablet.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images</p>\n<h3>2. Cassava Sciences</h3>\n<p>Shares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.</p>\n<p>According to the company, \"the ability to improve&nbsp;multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.</p>\n<p>Even though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>'s AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.</p>\n<p>So what makes Cassava Sciences a risky stock to buy?</p>\n<p>Before the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.</p>\n<p>At least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though&nbsp;that also means the potential rewards could be huge.</p>\n<p>Cassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> comfortable with the risk should consider initiating a (small) position in this healthcare stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Risk, High-Reward Stocks That Could Go to the Moon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Risk, High-Reward Stocks That Could Go to the Moon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153755876","content_text":"There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.\nBut others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: Planet 13 Holdings (OTC:PLNH.F) and Cassava Sciences (NASDAQ:SAVA).\n\nPLNHF data by YCharts\n1. Planet 13 Holdings\nWall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has one of the most innovative business models.\nThe company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.\nWith a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.\nPlanet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including New York City, Washington D.C., and Miami.\nThis master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.\nManagement's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the one in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.\nIf Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.\n\nImage source: Getty Images\n2. Cassava Sciences\nShares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.\nAccording to the company, \"the ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.\nEven though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of Biogen's AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.\nSo what makes Cassava Sciences a risky stock to buy?\nBefore the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.\nAt least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though that also means the potential rewards could be huge.\nCassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. Investors comfortable with the risk should consider initiating a (small) position in this healthcare stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159478492,"gmtCreate":1624978507716,"gmtModify":1703849400597,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Waiting for below&nbsp;$20","listText":"Waiting for below&nbsp;$20","text":"Waiting for below $20","images":[{"img":"https://static.tigerbbs.com/d13900ebf95ba98e9c5cf77a09cbea9b","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159478492","isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":126181559,"gmtCreate":1624547575071,"gmtModify":1703840110096,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"[Glance]&nbsp;","listText":"[Glance]&nbsp;","text":"[Glance]","images":[{"img":"https://static.tigerbbs.com/f96a3fd5594599594dd744ab43b84bcc","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126181559","isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}